Plasma phenylethylamine in schizophrenic patients
Plasma samples were collected from 41 patients who met DSM-III criteria for schizophrenia and from 34 healthy controls. Phenylethylamine (PE) levels were determined using a gas chromatography-mass spectrometry negative chemical ionization method. PE was significantly higher in the schizophrenic pati...
Gespeichert in:
Veröffentlicht in: | Biological psychiatry (1969) 1991-07, Vol.30 (2), p.145-150 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 150 |
---|---|
container_issue | 2 |
container_start_page | 145 |
container_title | Biological psychiatry (1969) |
container_volume | 30 |
creator | O'Reilly, R. Davis, B.A. Durden, D.A. Thorpe, L. Machnee, H. Boulton, A.A. |
description | Plasma samples were collected from 41 patients who met DSM-III criteria for schizophrenia and from 34 healthy controls. Phenylethylamine (PE) levels were determined using a gas chromatography-mass spectrometry negative chemical ionization method. PE was significantly higher in the schizophrenic patients compared with controls. There were no differences in PE between paranoid and nonparanoid patients. Plasma PE did not appear to be influenced by the severity of schizophrenic symptoms (rated by BPRS, SANS, and SAPS) or by the amount of dietary phenylalanine ingested within 24 hr of testing. Plasma PE did not correlate with current or past exposure to neuroleptic medication. It was not possible, however, to test individual patients during two periods when they were taking and not taking medication. Thus it is possible that neuroleptic exposure may have confounded the results. This study provides further evidence that PE excess may play a role in the etiology of schizophrenia but does not support previous studies which suggest that such an abnormality is limited to the paranoid subgroup. |
doi_str_mv | 10.1016/0006-3223(91)90168-L |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72112168</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>000632239190168L</els_id><sourcerecordid>72112168</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-69e2ccf67ae99ad4a2c035a51730923e2679726df9176807a68304a350c33ef43</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMo67r6DxR6ENFDNR9t0lwEWfyCBT3oOYzplEb6ZdIV1l9v1l305ilM5nmHmYeQY0YvGWXyilIqU8G5ONfsQsefIl3skCkrlEh5Rvkumf4i--QghPdYKs7ZhEyYZpxROSXsuYHQQjLU2K0aHOtVA63rMHFdEmztvvqh9tg5mwwwOuzGcEj2KmgCHm3fGXm9u32ZP6SLp_vH-c0itaKQYyo1cmsrqQC1hjIDbqnIIWdKUM0Fcqm04rKsNFOyoApkIWgGIqdWCKwyMSNnm7mD7z-WGEbTumCxaaDDfhmM4izeEFMzkm1A6_sQPFZm8K4FvzKMmrUps9Zg1hqMZubHlFnE2Ml2_vKtxfIvtFET-6fbPgQLTeWhsy78YnmudUZFxK43GEYXnw69CTZ6slg6j3Y0Ze_-3-MbZpiC5g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72112168</pqid></control><display><type>article</type><title>Plasma phenylethylamine in schizophrenic patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>O'Reilly, R. ; Davis, B.A. ; Durden, D.A. ; Thorpe, L. ; Machnee, H. ; Boulton, A.A.</creator><creatorcontrib>O'Reilly, R. ; Davis, B.A. ; Durden, D.A. ; Thorpe, L. ; Machnee, H. ; Boulton, A.A.</creatorcontrib><description>Plasma samples were collected from 41 patients who met DSM-III criteria for schizophrenia and from 34 healthy controls. Phenylethylamine (PE) levels were determined using a gas chromatography-mass spectrometry negative chemical ionization method. PE was significantly higher in the schizophrenic patients compared with controls. There were no differences in PE between paranoid and nonparanoid patients. Plasma PE did not appear to be influenced by the severity of schizophrenic symptoms (rated by BPRS, SANS, and SAPS) or by the amount of dietary phenylalanine ingested within 24 hr of testing. Plasma PE did not correlate with current or past exposure to neuroleptic medication. It was not possible, however, to test individual patients during two periods when they were taking and not taking medication. Thus it is possible that neuroleptic exposure may have confounded the results. This study provides further evidence that PE excess may play a role in the etiology of schizophrenia but does not support previous studies which suggest that such an abnormality is limited to the paranoid subgroup.</description><identifier>ISSN: 0006-3223</identifier><identifier>EISSN: 1873-2402</identifier><identifier>DOI: 10.1016/0006-3223(91)90168-L</identifier><identifier>PMID: 1912106</identifier><identifier>CODEN: BIPCBF</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Adult and adolescent clinical studies ; Age Factors ; Biological and medical sciences ; Female ; Gas Chromatography-Mass Spectrometry ; Humans ; Male ; Medical sciences ; Middle Aged ; Phenethylamines - blood ; Psychiatric Status Rating Scales ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychoses ; Schizophrenia - blood ; Schizophrenia - diagnosis ; Schizophrenic Psychology ; Sex Factors</subject><ispartof>Biological psychiatry (1969), 1991-07, Vol.30 (2), p.145-150</ispartof><rights>1991</rights><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-69e2ccf67ae99ad4a2c035a51730923e2679726df9176807a68304a350c33ef43</citedby><cites>FETCH-LOGICAL-c386t-69e2ccf67ae99ad4a2c035a51730923e2679726df9176807a68304a350c33ef43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0006-3223(91)90168-L$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5599403$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1912106$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>O'Reilly, R.</creatorcontrib><creatorcontrib>Davis, B.A.</creatorcontrib><creatorcontrib>Durden, D.A.</creatorcontrib><creatorcontrib>Thorpe, L.</creatorcontrib><creatorcontrib>Machnee, H.</creatorcontrib><creatorcontrib>Boulton, A.A.</creatorcontrib><title>Plasma phenylethylamine in schizophrenic patients</title><title>Biological psychiatry (1969)</title><addtitle>Biol Psychiatry</addtitle><description>Plasma samples were collected from 41 patients who met DSM-III criteria for schizophrenia and from 34 healthy controls. Phenylethylamine (PE) levels were determined using a gas chromatography-mass spectrometry negative chemical ionization method. PE was significantly higher in the schizophrenic patients compared with controls. There were no differences in PE between paranoid and nonparanoid patients. Plasma PE did not appear to be influenced by the severity of schizophrenic symptoms (rated by BPRS, SANS, and SAPS) or by the amount of dietary phenylalanine ingested within 24 hr of testing. Plasma PE did not correlate with current or past exposure to neuroleptic medication. It was not possible, however, to test individual patients during two periods when they were taking and not taking medication. Thus it is possible that neuroleptic exposure may have confounded the results. This study provides further evidence that PE excess may play a role in the etiology of schizophrenia but does not support previous studies which suggest that such an abnormality is limited to the paranoid subgroup.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Age Factors</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Gas Chromatography-Mass Spectrometry</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Phenethylamines - blood</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychoses</subject><subject>Schizophrenia - blood</subject><subject>Schizophrenia - diagnosis</subject><subject>Schizophrenic Psychology</subject><subject>Sex Factors</subject><issn>0006-3223</issn><issn>1873-2402</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQhoMo67r6DxR6ENFDNR9t0lwEWfyCBT3oOYzplEb6ZdIV1l9v1l305ilM5nmHmYeQY0YvGWXyilIqU8G5ONfsQsefIl3skCkrlEh5Rvkumf4i--QghPdYKs7ZhEyYZpxROSXsuYHQQjLU2K0aHOtVA63rMHFdEmztvvqh9tg5mwwwOuzGcEj2KmgCHm3fGXm9u32ZP6SLp_vH-c0itaKQYyo1cmsrqQC1hjIDbqnIIWdKUM0Fcqm04rKsNFOyoApkIWgGIqdWCKwyMSNnm7mD7z-WGEbTumCxaaDDfhmM4izeEFMzkm1A6_sQPFZm8K4FvzKMmrUps9Zg1hqMZubHlFnE2Ml2_vKtxfIvtFET-6fbPgQLTeWhsy78YnmudUZFxK43GEYXnw69CTZ6slg6j3Y0Ze_-3-MbZpiC5g</recordid><startdate>19910715</startdate><enddate>19910715</enddate><creator>O'Reilly, R.</creator><creator>Davis, B.A.</creator><creator>Durden, D.A.</creator><creator>Thorpe, L.</creator><creator>Machnee, H.</creator><creator>Boulton, A.A.</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19910715</creationdate><title>Plasma phenylethylamine in schizophrenic patients</title><author>O'Reilly, R. ; Davis, B.A. ; Durden, D.A. ; Thorpe, L. ; Machnee, H. ; Boulton, A.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-69e2ccf67ae99ad4a2c035a51730923e2679726df9176807a68304a350c33ef43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Age Factors</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Gas Chromatography-Mass Spectrometry</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Phenethylamines - blood</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychoses</topic><topic>Schizophrenia - blood</topic><topic>Schizophrenia - diagnosis</topic><topic>Schizophrenic Psychology</topic><topic>Sex Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>O'Reilly, R.</creatorcontrib><creatorcontrib>Davis, B.A.</creatorcontrib><creatorcontrib>Durden, D.A.</creatorcontrib><creatorcontrib>Thorpe, L.</creatorcontrib><creatorcontrib>Machnee, H.</creatorcontrib><creatorcontrib>Boulton, A.A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biological psychiatry (1969)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>O'Reilly, R.</au><au>Davis, B.A.</au><au>Durden, D.A.</au><au>Thorpe, L.</au><au>Machnee, H.</au><au>Boulton, A.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma phenylethylamine in schizophrenic patients</atitle><jtitle>Biological psychiatry (1969)</jtitle><addtitle>Biol Psychiatry</addtitle><date>1991-07-15</date><risdate>1991</risdate><volume>30</volume><issue>2</issue><spage>145</spage><epage>150</epage><pages>145-150</pages><issn>0006-3223</issn><eissn>1873-2402</eissn><coden>BIPCBF</coden><abstract>Plasma samples were collected from 41 patients who met DSM-III criteria for schizophrenia and from 34 healthy controls. Phenylethylamine (PE) levels were determined using a gas chromatography-mass spectrometry negative chemical ionization method. PE was significantly higher in the schizophrenic patients compared with controls. There were no differences in PE between paranoid and nonparanoid patients. Plasma PE did not appear to be influenced by the severity of schizophrenic symptoms (rated by BPRS, SANS, and SAPS) or by the amount of dietary phenylalanine ingested within 24 hr of testing. Plasma PE did not correlate with current or past exposure to neuroleptic medication. It was not possible, however, to test individual patients during two periods when they were taking and not taking medication. Thus it is possible that neuroleptic exposure may have confounded the results. This study provides further evidence that PE excess may play a role in the etiology of schizophrenia but does not support previous studies which suggest that such an abnormality is limited to the paranoid subgroup.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>1912106</pmid><doi>10.1016/0006-3223(91)90168-L</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-3223 |
ispartof | Biological psychiatry (1969), 1991-07, Vol.30 (2), p.145-150 |
issn | 0006-3223 1873-2402 |
language | eng |
recordid | cdi_proquest_miscellaneous_72112168 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Adult Adult and adolescent clinical studies Age Factors Biological and medical sciences Female Gas Chromatography-Mass Spectrometry Humans Male Medical sciences Middle Aged Phenethylamines - blood Psychiatric Status Rating Scales Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychoses Schizophrenia - blood Schizophrenia - diagnosis Schizophrenic Psychology Sex Factors |
title | Plasma phenylethylamine in schizophrenic patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T06%3A17%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20phenylethylamine%20in%20schizophrenic%20patients&rft.jtitle=Biological%20psychiatry%20(1969)&rft.au=O'Reilly,%20R.&rft.date=1991-07-15&rft.volume=30&rft.issue=2&rft.spage=145&rft.epage=150&rft.pages=145-150&rft.issn=0006-3223&rft.eissn=1873-2402&rft.coden=BIPCBF&rft_id=info:doi/10.1016/0006-3223(91)90168-L&rft_dat=%3Cproquest_cross%3E72112168%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72112168&rft_id=info:pmid/1912106&rft_els_id=000632239190168L&rfr_iscdi=true |